Skip to main content

Table 2 Experimental subunit vaccines against Mycoplasma hyopneumoniae tested in mice.

From: Perspectives for improvement of Mycoplasma hyopneumoniae vaccines in pigs

Antigen Vaccine type Adjuvant Route Nb of vaccinations Humoral response CMI responsea Other/comments References
Serum BALFb
P71 Subunit Mycobacterium tuberculosis ESAT-6 recombinant protein IM 2 IgG1, IgG2a
IgG2a/IgG1 ≈1 (with) < 1 (without adjuvant)
  IFN-γ, low Il-10   [82]
P97 (R1) Subunit and its chimeric from with LTBb   IM or IN 3 IgG, IgG1, IgG2a (only with chimeric form)
IM: IgG2a/IgG1 = 1.2
IN: IgG2a/IgG1 = 0.6
IgA (only with chimeric form) IFN-γ response (only with chimeric form and IN application) No anti-R1 antibodies with commercial bacterin [83]
P97 (R1,R1R2) Subunit and their chimeric forms with LTB Montanide IMS 1113 IM 3 IgG IgA, IgG IFN-γ Highest humoral response with chimeric forms [84]
HSP70 Subunit Nanoparticles SBa-15 and SBa-16, Aluminium IP 3 IgG   Only in SBa-15 group; IFN-γ, Il-4, Il-10 Effect SBa-15 comparable to Aluminium [85]
P97R1, P46, P95, P42 Chimeric – recombinant E. coli bacterin Oil adjuvant (AddaVax™) (for chimeric) IM 2 IgG, IgG1, IgG2a (IgG2a /IgG1≈0.8)    Antibodies against each antigen; higher response in chimeric group [86]
  1. IM, Intramuscular; IN, Intranasal; IP, Intraperitoneal.
  2. aCMI responses were tested by stimulation of splenocytes.
  3. bBALF bronchoalveolar lavage fluid.
  4. cLTB B subunit of heat-labile enterotoxin of E. coli.